Corvus Pharmaceuticals (CRVS)

• Market cap: $566M
• 1 day: -3.44%
• 5 days: 6.15%
• 1 month: 4.26%
• 3 months: 63.23%
• 6 months: 116.86%
• Year to date: 39.78%
• 1 year: -12.15%
• 5 years: 99.74%
• 10 years: -46.74%
• Sector: Healthcare
• Industry: Biotechnology

About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Employees: 31